Phagocytosis checkpoints as new targets for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Adaptive immune checkpoint inhibitors have improved cancer treatment outcomes.
• Innate immune checkpoints also play a critical role in tumor immune evasion by inhibiting phagocytosis and immune sensing.
• Targeting innate immune checkpoints presents a promising avenue for novel cancer immunotherapies.

Purpose of the Study:

• To review the mechanisms by which cancer cells evade immune surveillance through phagocytosis disruption.
• To discuss the impact of phagocytosis checkpoint blockade on anti-tumour immunity.
• To explore the potential of targeting innate immune checkpoints for combination immunotherapy strategies.

Main Methods:

• Literature review of preclinical studies and early clinical data on innate immune checkpoints.
• Analysis of tumor-intrinsic processes affecting immune surveillance.
• Synthesis of current understanding on phagocytosis and innate immune sensing in cancer.

Main Results:

• Cancer cells exploit innate immune checkpoints to evade phagocytic clearance and suppress immune sensing.
• Blocking phagocytosis checkpoints, such as the CD47-signal-regulatory protein α (SIRPα) axis, can induce anti-tumour immune responses.
• Innate immune cells are crucial for priming adaptive immune responses.

Conclusions:

• Targeting innate immune checkpoints offers a potential strategy to overcome tumor immune escape.
• Combination immunotherapies modulating both innate and adaptive responses may lead to more effective cancer treatments.
• Further understanding of tumor-intrinsic immune evasion mechanisms is essential for developing advanced immunotherapies.